Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

Laura E. Niklason net worth and biography

Laura Niklason Biography and Net Worth

CEO of Humacyte

Dr. Niklason is the founder of Humacyte and has served as President and Chief Executive Officer since November 2020 and as a member of the Humacyte Board since 2004. Dr. Niklason holds a Ph.D. in Biophysics from the University of Chicago and an M.D. from the University of Michigan. Dr. Niklason has been a member of Humacyte’s Board since the Company’s founding.

What is Laura E. Niklason's net worth?: The estimated net worth of Laura E. Niklason is at least $22.91 million as of September 14th, 2023. Dr. Niklason owns 6,191,140 shares of Humacyte stock worth more than $22,907,218 as of April 19th. This net worth evaluation does not reflect any other investments that Dr. Niklason may own. Additionally, Dr. Niklason receives an annual salary of $717,850.00 as CEO at Humacyte. Learn More about Laura E. Niklason's net worth.
How old is Laura E. Niklason?: Dr. Niklason is currently 61 years old. There are 5 older executives and no younger executives at Humacyte. Learn More on Laura E. Niklason's age.
What is Laura E. Niklason's salary?: As the CEO of Humacyte, Inc., Dr. Niklason earns $717,850.00 per year. Learn More on Laura E. Niklason's salary.
How do I contact Laura E. Niklason?: The corporate mailing address for Dr. Niklason and other Humacyte executives is 1177 AVENUE OF THE AMERICAS 5TH FLOOR, NEW YORK NY, 10036. Humacyte can also be reached via phone at 919-313-9633 and via email at [email protected]. Learn More on Laura E. Niklason's contact information.
Has Laura E. Niklason been buying or selling shares of Humacyte?: Laura E. Niklason has not been actively trading shares of Humacyte over the course of the past ninety days. Most recently, Laura E. Niklason sold 2,000,000 shares of the business's stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $2.78, for a transaction totalling $5,560,000.00. Following the completion of the sale, the chief executive officer now directly owns 6,191,140 shares of the company's stock, valued at $17,211,369.20. Learn More on Laura E. Niklason's trading history.
Who are Humacyte's active insiders?: Humacyte's insider roster includes Michael Constantino (Director), Brady Dougan (Director), and Laura Niklason (CEO). Learn More on Humacyte's active insiders.
Are insiders buying or selling shares of Humacyte?: During the last twelve months, insiders at the sold shares 8 times. They sold a total of 11,809,209 shares worth more than $33,429,404.91. The most recent insider tranaction occured on September, 14th when CEO Laura E Niklason sold 2,000,000 shares worth more than $5,560,000.00. Insiders at Humacyte own 23.1% of the company. Learn More about insider trades at Humacyte.
Information on this page was last updated on 9/14/2023.

Laura E. Niklason Insider Trading History at Humacyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/14/2023	Sell	2,000,000	$2.78	$5,560,000.00	6,191,140
8/21/2023	Sell	602,443	$3.39	$2,042,281.77	8,191,140
8/17/2023	Sell	570,174	$3.68	$2,098,240.32	9,420,562
6/15/2023	Sell	500,000	$3.12	$1,560,000.00	9,990,736
6/13/2023	Sell	4,875,000	$2.60	$12,675,000.00	10,490,736
5/25/2023	Sell	2,625,000	$2.75	$7,218,750.00	15,365,736
12/15/2022	Sell	93,426	$2.63	$245,710.38	18,230,274
12/13/2022	Sell	330,000	$2.84	$937,200.00	18,600,004
9/15/2022	Buy	2,000	$4.14	$8,280.00	1,160,240
5/23/2022	Buy	10,000	$4.83	$48,300.00	1,158,240
12/15/2021	Sell	125,000	$8.88	$1,110,000.00

Laura E. Niklason Buying and Selling Activity at Humacyte

Humacyte Company Overview

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Today's Range

Now: $3.70

$3.55

$4.11

50 Day Range

MA: $3.53

$2.87

$4.84

2 Week Range

Now: $3.70

$1.96

$5.60

Volume

4,895,449 shs

Average Volume

1,088,435 shs

Market Capitalization

$440.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.46

Secret Bull Market Starts in This Unusual Sector

From Altimetry | Ad

Click for my No. 1 investment, all free of charge, click here.

Laura Niklason Biography and Net Worth

What is Laura E. Niklason's net worth?

How old is Laura E. Niklason?

What is Laura E. Niklason's salary?

How do I contact Laura E. Niklason?

Has Laura E. Niklason been buying or selling shares of Humacyte?

Who are Humacyte's active insiders?

Are insiders buying or selling shares of Humacyte?